Revenue growth rates for CRISPR Therapeutics fluctuate significantly from year to year, which is characteristic of clinical-stage and commercial-stage gene-editing biopharmaceutical enterprises. Financial reporting shows that top-line figures are heavily driven by the timing of major strategic collaboration agreements, upfront licensing payments, and joint development milestones with pharmaceutical partners rather than steady commercial sales. Consequently, year-over-year percentage growth rates display wide variances reflecting partnership inflows and grant funding.